Drug combination for acute myeloid leukemia that came back or resisted treatment
Tests venetoclax, chidamide, chiglitazar sodium in hard-to-treat acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Key facts
- Where
- Xiamen, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose acute myeloid leukemia (AML) has come back or has not responded to earlier treatment. It tests venetoclax, chidamide and chiglitazar sodium together.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Acute myeloid leukemia that came back (relapsed) or did not go into remission after at least one earlier treatment. AML that grew out of myelodysplastic syndrome or myeloproliferative neoplasms can also join.
- Earlier treatment
- At least one earlier treatment for AML. An earlier stem cell transplant is allowed, but not if graft-versus-host disease or ongoing immunosuppressive treatment is present.
Main reasons for not taking part
- Acute promyelocytic leukemia
- Active leukemia in the central nervous system
- Significant heart disease, such as heart failure or a heart attack within 1 year
- Active, uncontrolled severe infection
- Earlier solid organ transplant
Read by machine on 9 November 2026.
Where in China
- The First Affiliated hospital of Xiamen UniversityXiamen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Xiamen University
- Trial code
- NCT07783100
- Record updated
- 24 August 2026
- Original description
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).Read full original descriptionShow less
A Multicenter, Prospective, Single-Arm Study of Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Inclusion: Histologically confirmed acute myeloid leukemia (AML) with relapsed or refractory disease, including:; Refractory AML, defined as failure to achieve remission after at least one prior treatment; Relapsed AML, defined as ≥5% blasts in the bone marrow after a previous remission; AML arising from myelodysplastic syndrome (including CMML) or myeloproliferative neoplasms (secondary AML or therapy-related AML [t-AML]) is also eligible; Age ≥18 years, regardless of sex, with an expected survival of >3 months; Estimated creatinine clearance ≥50 mL/min; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × the upper limit of normal (ULN), unless the abnormality is considered attributable to leukemic organ involvement; total bilirubin ≤3.0 × ULN, unless the abnormality is considered attributable to leukemic organ involvement; Eastern Cooperative Oncology Group (ECOG) performance status ≤2; Participants must not be pregnant and must agree to use effective contraception during study treatment; Ability to understand the study and willingness to provide written informed consent.
Exclusion: Other non-hematologic malignancies within the previous 2 years; Previous solid organ transplantation. Prior stem cell transplantation (SCT) is permitted; however, patients with graft-versus-host disease (GVHD) or those receiving ongoing immunosuppressive or GVHD-directed therapy are not eligible; Active, uncontrolled severe infection; Psychiatric disorders that may interfere with participation in the study; Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study; Clinically significant cardiovascular disease, including any of the following:; Clinically significant QTc prolongation (QTc >450 ms in males or >470 ms in females); Ventricular tachycardia; Second-degree atrioventricular block; Myocardial infarction within 1 year prior to enrollment; Congestive heart failure; Coronary artery disease requiring medical treatment; Acute promyelocytic leukemia (APL); Active central nervous system leukemia.